COMP <GO>
BCRX vs MESO // EV/EBITDA & P/E VALUATION
BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Mesoblast Limited (NASDAQ) • 15-METRIC TALLY: BCRX 1
— MESO 1
■ METRIC PARITY
LAST: $8.52 (+1.79%) • MKT CAP: $2.18B
valuation
6.1x
LAST: $15.67 (+17.03%) • MKT CAP: $2.04B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. MESO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BCRX | MESO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 15.96% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.8 | 58.6 | -3.81 | MESO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 7.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.18B | $2.04B | $138.7M | BCRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BCRX REV | MESO REV | BCRX GROSS % | MESO GROSS % | BCRX FCF | MESO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | $347.4M | — |
| FY 2024 | $0 | — | — | — | -$52.0M | — |
| FY 2023 | $0 | — | — | — | -$95.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
MESO // BETA —